Enhanced Adaptive Immune Response Systems for MICA-Expressing Cancers

A next-generation system for adaptive immune response enhancement, integrating bi-specific T-cell engagers, machine learning-based dosing regimens, and nanoparticle-conjugated CAR-T cell therapies to combat MICA-expressing cancers.

The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, and cells for treating MICA-expressing cancers. However, these approaches have limitations in terms of efficacy, safety, and personalized treatment. The new inventive concept addresses these limitations by introducing a multi-faceted system that adapts to individual patient needs and enhances anti-tumor activity.

The system comprises a bi-specific T-cell engager that directs T-cell effector responses against MICA-expressing cancer cells, a machine learning module for predicting optimal T-cell engager dosing regimens based on patient-specific genomic profiles, and a composition of matter featuring a MICA-targeting CAR-T cell and a bi-specific T-cell engager conjugated to a nanoparticle for enhanced tumor penetration. Additionally, the system includes a device for in vivo monitoring of MICA-expressing cancer cells and a computer-implemented method for identifying novel MICA-binding epitopes.

The new claims introduce a paradigm shift in cancer treatment by integrating machine learning, bi-specific T-cell engagers, and nanoparticle-conjugated CAR-T cell therapies. The inventive step lies in the combination of these components to create a personalized, adaptive, and highly effective system for combating MICA-expressing cancers.

Alternative embodiments may include variations in the bi-specific T-cell engager design, different nanoparticle conjugation strategies, and the integration of additional machine learning algorithms for predicting treatment outcomes. Variations may also include the use of different types of immune cells or targets, as well as the incorporation of gene editing technologies to enhance the system's efficacy.

The enhanced adaptive immune response system has significant commercial potential in the cancer treatment market, particularly for MICA-expressing cancers. The system's personalized and adaptive nature makes it an attractive solution for pharmaceutical companies, biotech startups, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.